CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 14 enrolled
Drug / intervention
DDAVP injection (desmopressin acetate)drug
Likely dose
DDAVP injection (desmopressin acetate) 0.4 mcg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00961532
NCT00961532Phase 2Completed
CompareCT.gov

Improving Platelet Activity for Cerebral Hemorrhage Treatment - DDAVP Proof of Concept

Northwestern University·interventional·Posted Aug 19, 2009·Updated Aug 28, 2014

In Brief

A Phase 2 clinical trial evaluating DDAVP injection (desmopressin acetate) for Intracerebral Hemorrhage. Completed, enrolled 14 participants across 1 site.

Detailed Summary

The investigators intend to show that DDAVP improves platelet activity from baseline to 60 minutes after treatment start.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIntracerebral Hemorrhage
CountriesUnited States
CollaboratorsNorthwestern Memorial Hospital

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 19, 2009
Enrollment StartDec 1, 2010
Primary CompletionDec 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 16.9 years ago

Interventions

DDAVP injection (desmopressin acetate)drug

0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes